Drop in Biological Initiation for Patients with Psoriasis During the COVID-19 Pandemic

Overview

Journal Br J Dermatol

Publisher Oxford University Press

Specialty Dermatology

Date 2021 Apr 24

PMID 33894022

Citations 7

Authors

L Penso

R Dray-Spira

A Weill

M Zureik

E Sbidian

Affiliations

Soon will be listed here.

Citing Articles

Enhanced impact of psoriasis severity on the treatment demands of patients during the COVID-19 pandemic: a cross-sectional study based on a national psoriasis registry in China.

Yang Z, Jin Y, Wang M, Li R, Li W, Li H BMJ Open. 2024; 14(2):e079627.

PMID: 38367975 PMC: 10875510. DOI: 10.1136/bmjopen-2023-079627.

A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: Focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting.

Ghoreishi Amin N, Khosravi S, Atefi N, Seirafianpour F, Farhoodi S, Goodarzi A Immun Inflamm Dis. 2023; 11(11):e1063.

PMID: 38018599 PMC: 10629237. DOI: 10.1002/iid3.1063.

Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines.

Zureik M, Cuenot F, Weill A, Dray-Spira R Therapie. 2023; 78(5):553-557.

PMID: 36739224 PMC: 9851737. DOI: 10.1016/j.therap.2022.12.013.

Impact of coronavirus disease 2019 on contraception use in France.

Roland N, Drouin J, Desplas D, Duranteau L, Cuenot F, Dray-Spira R Therapie. 2023; 78(5):593-603.

PMID: 36732137 PMC: 9851715. DOI: 10.1016/j.therap.2023.01.002.

Effect of COVID-19 pandemic on psoriatic patients dermatology admissions and biologic treatment adherences: A single-center retrospective study.

Ozdemir A, Hayran Y, Sen O, Aktas A J Cosmet Dermatol. 2021; 20(11):3362-3363.

PMID: 34633748 PMC: 8662222. DOI: 10.1111/jocd.14512.

References

Davila-Seijo P, Dauden E, Descalzo M, Carretero G, Carrascosa J, Vanaclocha F . Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. J Invest Dermatol. 2016; 137(2):313-321. DOI: 10.1016/j.jid.2016.08.034. View

Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J . Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2018; 180(1):86-93. DOI: 10.1111/bjd.16809. View

Yiu Z, Ashcroft D, Evans I, McElhone K, Lunt M, Smith C . Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol. 2018; 180(2):329-337. PMC: 7379582. DOI: 10.1111/bjd.17036. View

Mahil S, Dand N, Mason K, Yiu Z, Tsakok T, Meynell F . Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2020; 147(1):60-71. PMC: 7566694. DOI: 10.1016/j.jaci.2020.10.007. View

Lebwohl M, Rivera-Oyola R, Murrell D . Should biologics for psoriasis be interrupted in the era of COVID-19?. J Am Acad Dermatol. 2020; 82(5):1217-1218. PMC: 7156810. DOI: 10.1016/j.jaad.2020.03.031. View